drugset / Trial / NCT02354547
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the dose limiting toxicities and recommended phase 2 dose of SGT-53 alone and in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory solid tumors.
Timeline
- Start
- 2014-12
- Primary completion
- 2027-12
- Completion
- 2027-12
Outcome
Outcome not reported
Stopped (Enrollment): “slow recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 250 mg/m2 | Intravenous |
| Subject | SGT-53 | Other / unclassified | 0.7 mg/m2 | — |
| Subject | SGT-53 | Other / unclassified | 1.4 mg/m2 | — |
| Subject | SGT-53 | Other / unclassified | 2.1 mg/m2 | — |
| Subject | Topotecan | Small molecule | 0.75 mg/m2 | Intravenous |